Taken together, our study revealed evidence-based validation of echocardiographic variables to determine risk status and predict prognosis in patients with SSc-associated PAH and implied that the TAPSE/PASP ratio is potentially appropriate for further clinical applications in severity identification, treatment decision, prognosis prediction, and follow-up. The gene discussed is CPB1; the disease is systemic sclerosis.